188Re-HEDP therapy in the therapy of painful bone metastases
نویسندگان
چکیده
منابع مشابه
Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
UNLABELLED This retrospective study compared the effects of single and multiple administrations of (186)Re-hydroxyethylidenediphosphonate ((186)Re-HEDP) on palliation and survival of prostate cancer patients presenting with more than 5 skeletal metastases. METHODS A total of 60 patients were divided into 3 groups. Group A (n = 19) consisted of patients who had received a single injection; gro...
متن کاملEffectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases
Introduction: Bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188Re-hydroxyethylidene diphosphonate (188Re-HEDP) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of ...
متن کاملTeletherapy and radiopharmaceutical therapy of painful bone metastases.
Bone pain from metastatic disease is most common in cancers of the breast, prostate, and lung. Despite the World Health organization algorithm for treating such pain, the outcomes are not often satisfactory. In 2005, there will be 3 radiopharmaceuticals available in the United States that can reduce or relieve bone pain caused by osteoblastic metastases with apparently equal efficacy. Phosphoru...
متن کاملLiver and lymph node metastases of prostate cancer visualized on post-therapy imaging after treatment with 188Re-HEDP.
A 76-year-old man with bone metastases of prostate cancer diagnosed a year ago was admitted for relief of bone pain (visual analogue scale: 90%) most markedly in cervical spine and upper extremities due to skeletal metastases. His serum prostate specific antigen level was markedly increased (351 ng/ml). After documentation of sufficient tracer uptake in multiple bone metastases on whole-body 99...
متن کاملStrontium-89 Therapy in Painful Bony Metastases
Strontium-89 (Sr), a bone-seeking radiopharmaceutical, has been used successfully in recent trials to palliate bone pain secondary to metastatic disease. The use of this beta emitter in systemic radionuclide therapy should become an integral part in the management of many patients with metastatic disease to the bone. Intravenous Sr may be used in conjunction with standard chemotherapy and exter...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Nuclear Medicine
سال: 2018
ISSN: 1450-1147
DOI: 10.4103/wjnm.wjnm_85_17